Mega Medtech M&A Momentum In 2015
Executive Summary
Medtech M&A activity has been on the rise for several years along with a surge in the number of higher-valued mega-deals, those worth at least $1 billion. Yet a survey of all deals with known values indicates that median deal value has actually declined.
You may also be interested in...
Institutionalizing M&A Excellence In Health Care
M&A deals, particularly smaller ones, are the lifeblood of the health care industry. Despite evident success in dealmaking, McKinsey says that pharma and medtech firms can benefit by bringing better consistency, transparency and accountability to their M&A programs.
Institutionalizing M&A Excellence In Health Care
M&A deals, particularly smaller ones, are the lifeblood of the health care industry. Despite evident success in dealmaking, McKinsey says that pharma and medtech firms can benefit by bringing better consistency, transparency and accountability to their M&A programs.
Device/Diagnostics Quarterly Deal Statistics, Q4 2015
At $1.2 billion, Q4 device financing was the second-lowest quarter of 2015; M&A dollar volume was also low, but included multiple deals across various cardiovascular markets. Diagnostics financing was also down in Q4, totaling $403 million; acquisitions were worth $441 million.